Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Migraine, Nausea
Clinical narrative: This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 63 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 19Mar2021 15:00 (Lot number: EN6207) at the age of 63 years as dose 1, single and administered in arm right, administration date 09Apr2021 15:00 (Lot number: ER8733) as dose 2, single for Covid-19 immunisation. Relevant medical history included: "Neuropathies", start date: 2004 (ongoing), notes: Raynaud's, Neuropathy, Periodic asthma-place me at risk for complications from Covid. , Illness/AE: Neuropathy, Stop Date: Ongoing, Pertinent Details: secondary to chemo 2004; "Raynaud's", start date: 2004 (ongoing), notes: Raynaud's, Neuropathy, Periodic asthma-place me at risk for complications from Covid. Illness/AE: Raynaud's, Stop Date: Ongoing, Pertinent Details: secondary to chemo 2004; "spinal stenosis" (ongoing), notes: Illness/AE: Stenosis, Stop Date: Ongoing; "arthritis" (unspecified if ongoing); "Periodic asthma" (unspecified if ongoing), notes: Raynaud's, Neuropathy, Periodic asthma-place me at risk for complications from Covid; "chemo", start date: 2004 (unspecified if ongoing), notes: Pertinent Details: secondary to chemo 2004; "Migraine", start date: 1988 (ongoing), notes: Illness/AE: Migraine, Stop Date: Ongoing, Pertinent Details: since 1988- occasional; "SI Joint" (ongoing), notes: Reason for use: SI Joint, Route: Oral, Ongoing; "pain issues" (ongoing), notes: Reason for use: pain issues, Route: Oral, Ongoing; "cholesterol" (ongoing), notes: Reason for use: cholesterol, Route: Oral, Ongoing; "sleep" (ongoing), notes: Reason for use: sleep, Route: Oral, Ongoing. Concomitant medication(s) included: FLUZONE QUADRIVALENT, start date: 07Oct2021, stop date: 07Oct2021; HYDROCODONE taken for arthritis, stenosis, migraine (ongoing); MAGNESIUM OXIDE; CYCLOBENZAPRINE taken for sacroiliac joint dysfunction (ongoing); ALP taken for sleep disorder (ongoing); TYLENOL taken for pain (ongoing); PRAVASTATIN taken for blood cholesterol (ongoing). Past drug history included: Allergy: codeine, reaction(s): "Allergy"; Allergy: Demerol, reaction(s): "Allergy"; Allergy: Ultram, reaction(s): "Allergy"; Allergy: ergotamine, reaction(s): "Allergy". The following information was reported: NAUSEA (non-serious), outcome "unknown", described as "I felt the same level of nausea"; MIGRAINE (non-serious), outcome "unknown", described as "migraine"; CHILLS (non-serious), outcome "unknown", described as "chills". Additional information: The Booster had much more severe side effects than the first two doses. My joints hurt so that I could walk barely and my armpits hurt very badly. I felt the same level of nausea, migraine, and chills. I'm glad I didn't know beforehand because I might have missed the booster. I understand these effects to be a strong immune response which is good news and I'm very grateful to Pfizer for providing these vaccines. I won't tell anyone how awful I feel because I would not deter anyone. At one point though the side effects were scary and I thought how awful for those suffering Covid in the hospitals and dying. I am trying to convince my son who is in a Frontline occupation to get the booster. Still, I thought you should know the side effects were pretty rough. Still, I'm very grateful. Took hydrocodone though I had been greatly reduced. Pain subsided after 2.5 days. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Weakened immune system. Specific Relevant Test For Thromboembolic Events with Thrombocytopenia was unknown. Patient did not need emergency medical treatment due to the Booster. Children will be very wary if they have similar side effects. (Praying). No follow-up attempts are possible. No further information is expected. Follow-Up (05Nov2021): Follow-up attempts are completed. No further information is expected. Follow-up (05Nov2021): New information received from a contactable consumer. This consumer (patient) reported in response to consumer letter sent via follow-up letter which included that: Drug Lot number and Expiration date, Concomitant Drugs, Patient's Medical History and additional information. Follow-up attempts are completed. No further information is expected